In a study of 150 patients presenting with stage II /III breast cancer included in a clinical trial (AZURE), we found significant correlations between expression of IL-1B in the primary tumour and both disease recurrence at any site (P < 0.0001) and, specifically, metastasis to bone (P < 0.0001) after median follow up of 84 months. Here, IL1B is linked to neoplasm.